Table of Contents Author Guidelines Submit a Manuscript
Journal of Immunology Research
Volume 2014, Article ID 536050, 10 pages
http://dx.doi.org/10.1155/2014/536050
Research Article

Anti-Cyclic Citrullinated Peptide (Anti-CCP) and Anti-Mutated Citrullinated Vimentin (Anti-MCV) Relation with Extra-Articular Manifestations in Rheumatoid Arthritis

1Department of Internal Medicine—Rheumatology, Hospital General Regional 110, IMSS, Avenida Salto del Agua 2192, Colonia Jardines del Country, 44710 Guadalajara, Jal, Mexico
2Postdoctoral Program of the National Council of Science and Technology (CONACYT), 03940 Mexico City DF, Mexico
3Postgraduate Programs of Pharmacology and Public Health Sciences, University Center of Health Sciences (CUCS), University of Guadalajara, 44340 Guadalajara, Jal, Mexico
4Clinical epidemiology Research Unit, UMAE, Specialties Hospital, Western Medical Center, Mexican Institute for Social Security (IMSS), 44340 Guadalajara, Jal, Mexico
5Physiology Department, CUCS, University of Guadalajara Research Division, UMAE, CMNO, IMSS, 44340 Guadalajara, Jal, Mexico
6Department of Physiology, CUCS, University of Guadalajara, 44340 Guadalajara, Jal, Mexico
7Postgraduate Program of Biomedical Sciences (Immunology), CUCS, University of Guadalajara, 44340 Guadalajara, Jal, Mexico

Received 10 January 2014; Revised 21 February 2014; Accepted 2 March 2014; Published 7 April 2014

Academic Editor: Michael Mahler

Copyright © 2014 Laura Gonzalez-Lopez et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. M. Prete, V. Racanelli, L. Digiglio, A. Vacca, F. Dammacco, and F. Perosa, “Extra-articular manifestations of rheumatoid arthritis: an update,” Autoimmunity Reviews, vol. 11, pp. 123–131, 2011. View at Publisher · View at Google Scholar · View at Scopus
  2. C. Turesson, L. Jacobsson, and U. Bergström, “Extra-articular rheumatoid arthritis: prevalence and mortality,” Rheumatology, vol. 38, no. 7, pp. 668–674, 1999. View at Publisher · View at Google Scholar · View at Scopus
  3. C. Turesson, R. L. McClelland, T. J. H. Christianson, and E. L. Matteson, “Multiple extra-articular manifestations are associated with poor survival in patients with rheumatoid arthritis,” Annals of the Rheumatic Diseases, vol. 65, no. 11, pp. 1533–1534, 2006. View at Publisher · View at Google Scholar · View at Scopus
  4. C. Turesson, L. Jacobsson, U. Bergström, L. Truedsson, and G. Sturfelt, “Predictors of extra-articular manifestations in rheumatoid arthritis,” Scandinavian Journal of Rheumatology, vol. 29, no. 6, pp. 358–364, 2000. View at Publisher · View at Google Scholar · View at Scopus
  5. C. M. Weyand, C. Xie, and J. J. Goronzy, “Homozygosity for the HLA-DRB1 allele selects for extraarticular manifestations in rheumatoid arthritis,” Journal of Clinical Investigation, vol. 89, no. 6, pp. 2033–2039, 1992. View at Google Scholar · View at Scopus
  6. P. Taylor, J. Gartemann, J. Hsieh, and J. Creeden, “A systematic review of serum biomarkers anti-cyclic citrullinated Peptide and rheumatoid factor as tests for rheumatoid arthritis,” Autoimmune Diseases, vol. 2011, Article ID 815038, 18 pages, 2011. View at Publisher · View at Google Scholar
  7. C. Turesson, L. T. H. Jacobsson, G. Sturfelt, E. L. Matteson, L. Mathsson, and J. Rönnelid, “Rheumatoid factor and antibodies to cyclic citrullinated peptides are associated with severe extra-articular manifestations in rheumatoid arthritis,” Annals of the Rheumatic Diseases, vol. 66, no. 1, pp. 59–64, 2007. View at Publisher · View at Google Scholar · View at Scopus
  8. C. Korkmaz, T. Us, T. Kaşifoğlu, and Y. Akgün, “Anti-cyclic citrullinated peptide (CCP) antibodies in patients with long-standing rheumatoid arthritis and their relationship with extra-articular manifestations,” Clinical Biochemistry, vol. 39, pp. 961–965, 2006. View at Google Scholar
  9. H. Poulsom and P. J. Charles, “Antibodies to citrullinated vimentin are a specific and sensitive marker for the diagnosis of rheumatoid arthritis,” Clinical Reviews in Allergy and Immunology, vol. 34, no. 1, pp. 4–10, 2008. View at Publisher · View at Google Scholar · View at Scopus
  10. R. Sghiri, E. Bouajina, D. Bargaoui et al., “Value of anti-mutated citrullinated vimentin antibodies in diagnosing rheumatoid arthritis,” Rheumatology International, vol. 29, no. 1, pp. 59–62, 2008. View at Publisher · View at Google Scholar · View at Scopus
  11. C. Turesson, W. M. O'Fallon, C. S. Crowson, S. E. Gabriel, and E. L. Matteson, “Occurrence of extraarticular disease manifestations is associated with excess mortality in a community based cohort of patients with rheumatoid arthritis,” Journal of Rheumatology, vol. 29, no. 1, pp. 62–67, 2002. View at Google Scholar · View at Scopus
  12. C. Turesson, W. M. O'Fallon, C. S. Crowson, S. E. Gabriel, and E. L. Matteson, “Extra-articular disease manifestations in rheumatoid arthritis: incidence trends and risk factors over 46 years,” Annals of the Rheumatic Diseases, vol. 62, no. 8, pp. 722–727, 2003. View at Publisher · View at Google Scholar · View at Scopus
  13. A. Swaak, “Anemia of chronic disease in patients with rheumatoid arthritis: aspects of prevalence, outcome, diagnosis, and the effect of treatment on disease activity,” Journal of Rheumatology, vol. 33, no. 8, pp. 1467–1468, 2006. View at Google Scholar · View at Scopus
  14. M. J. Salinas, S. Retamozo, L. Vetorazzi et al., “Anticitrulin antibody and the extra-articular manifestations in rheumatoid arthritis,” Medicina: Buenos Aires, vol. 73, pp. 21–25, 2013. View at Google Scholar
  15. A. Rojas-Villarraga, J. Amaya-Amaya, A. Rodriguez-Rodriguez, R. D. Mantilla, and J. M. Anaya, “Introducing polyautoimmunity: secondary autoimmune diseases no longer exist,” Autoimmune Disease, vol. 2012, Article ID 254319, 9 pages, 2012. View at Publisher · View at Google Scholar
  16. F. Barcelos, I. Abreu, J. V. Patto, H. Trindade, and A. Teixeira, “Anti-cyclic citrullinated peptide antibodies and rheumatoid factor in Sjögren's syndrome,” Acta reumatológica portuguesa, vol. 34, no. 4, pp. 608–612, 2009. View at Google Scholar · View at Scopus
  17. J. M. Ponce Guarneros, A. D. Rocha Muñoz, J. I. Gamez Nava et al., “Association between anti-cyclic citrullinated peptide antibodies titres and the presence and severity of diffuse interstitial lung disease secondary to rheumatoid arthritis,” Arthritis & Rheumatology, pp. S175–S176, 2013. View at Google Scholar
  18. T. R. Mikuls, J. R. O'Dell, J. A. Stoner et al., “Association of rheumatoid arthritis treatment response and disease duration with declines in serum levels of IgM rheumatoid factor and anti-cyclic citrullinated peptide antibody,” Arthritis and Rheumatism, vol. 50, no. 12, pp. 3776–3782, 2004. View at Publisher · View at Google Scholar · View at Scopus
  19. P. Nicaise Roland, S. Grootenboer Mignot, A. Bruns et al., “Antibodies to mutated citrullinated vimentin for diagnosing rheumatoid arthritis in anti-CCP-negative patients and for monitoring infliximab therapy,” Arthritis Research & Therapy, vol. 10, no. 6, p. R142, 2008. View at Google Scholar · View at Scopus